Log in to save to my catalogue

Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoi...

Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoi...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4a50266632f84b4e81fbc224cb0b637d

Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation

About this item

Full title

Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation

Publisher

London: Nature Publishing Group UK

Journal title

Blood cancer journal (New York), 2024-10, Vol.14 (1), p.189-8, Article 189

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Autologous transplantation remains the standard of care for eligible multiple myeloma (MM) patients, yet optimal CD34
+
cell dose remains unclear. We conducted a retrospective study on MM patients undergoing upfront transplant between 2005 and 2021 and divided them into low (≤2.5 × 10
6
 cells/kg) and high (>2.5 × 10
6
 cells/kg)...

Alternative Titles

Full title

Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_4a50266632f84b4e81fbc224cb0b637d

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4a50266632f84b4e81fbc224cb0b637d

Other Identifiers

ISSN

2044-5385

E-ISSN

2044-5385

DOI

10.1038/s41408-024-01165-w

How to access this item